{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T16:31:43Z","timestamp":1793291503364,"version":"4.5.0"},"reference-count":91,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,5]],"date-time":"2022-10-05T00:00:00Z","timestamp":1664928000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004071","name":"Khon Kaen University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004071","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.eprac.2022.09.007","type":"journal-article","created":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T23:31:33Z","timestamp":1665099093000},"page":"69-79","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Phosphatonins: From Discovery to Therapeutics"],"prefix":"10.1016","volume":"29","author":[{"given":"Kittrawee","family":"Kritmetapak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3497-3057","authenticated-orcid":false,"given":"Rajiv","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eprac.2022.09.007_bib1","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1146\/annurev.physiol.69.040705.141729","article-title":"Phosphatonins and the regulation of phosphate homeostasis","volume":"69","author":"Berndt","year":"2007","journal-title":"Annu Rev Physiol"},{"key":"10.1016\/j.eprac.2022.09.007_bib2","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s00223-019-00636-8","article-title":"Phosphate as a signaling molecule","volume":"108","author":"Kritmetapak","year":"2021","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.eprac.2022.09.007_bib3","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1152\/physrev.00022.2017","article-title":"Phosphate as a signaling molecule and its sensing mechanism","volume":"98","author":"Michigami","year":"2018","journal-title":"Physiol Rev"},{"key":"10.1016\/j.eprac.2022.09.007_bib4","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s00223-020-00729-9","article-title":"Role of phosphate in biomineralization","volume":"108","author":"Bhadada","year":"2021","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.eprac.2022.09.007_bib5","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1681\/ASN.2021050610","article-title":"Novel insights into mechanisms of intestinal phosphate absorption in patients with chronic kidney disease","volume":"32","author":"Kritmetapak","year":"2021","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.eprac.2022.09.007_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1152\/physrev.00008.2019","article-title":"Phosphate transport in epithelial and nonepithelial tissue","volume":"101","author":"Hernando","year":"2021","journal-title":"Physiol Rev"},{"key":"10.1016\/j.eprac.2022.09.007_bib7","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s00424-018-2221-1","article-title":"The role of SLC34A2 in intestinal phosphate absorption and phosphate homeostasis","volume":"471","author":"Marks","year":"2019","journal-title":"Pflugers Arch"},{"key":"10.1016\/j.eprac.2022.09.007_bib8","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1093\/ndt\/gfaa156","article-title":"Evidence of an intestinal phosphate transporter alternative to type IIb sodium-dependent phosphate transporter in rats with chronic kidney disease","volume":"36","author":"Ichida","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.eprac.2022.09.007_bib9","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.2215\/CJN.09090911","article-title":"Clinical consequences of mutations in sodium phosphate cotransporters","volume":"7","author":"Lederer","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.eprac.2022.09.007_bib10","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s00424-018-2231-z","article-title":"Physiological regulation of phosphate by vitamin D, parathyroid hormone (PTH) and phosphate (Pi)","volume":"471","author":"Jacquillet","year":"2019","journal-title":"Pflugers Arch"},{"key":"10.1016\/j.eprac.2022.09.007_bib11","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1172\/JCI119289","article-title":"Role of microtubules in the rapid regulation of renal phosphate transport in response to acute alterations in dietary phosphate content","volume":"99","author":"Lotscher","year":"1997","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.eprac.2022.09.007_bib12","doi-asserted-by":"crossref","first-page":"F231","DOI":"10.1152\/ajprenal.00532.2010","article-title":"Dynamics of PTH-induced disassembly of Npt2a\/NHERF-1 complexes in living OK cells","volume":"300","author":"Weinman","year":"2011","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.eprac.2022.09.007_bib13","doi-asserted-by":"crossref","first-page":"F689","DOI":"10.1152\/ajprenal.00007.2009","article-title":"PiT-2 coming out of the pits","volume":"296","author":"Moe","year":"2009","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.eprac.2022.09.007_bib14","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1681\/ASN.2016070726","article-title":"Renal Fanconi syndrome and hypophosphatemic rickets in the absence of xenotropic and polytropic retroviral receptor in the nephron","volume":"28","author":"Ansermet","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.eprac.2022.09.007_bib15","doi-asserted-by":"crossref","first-page":"F350","DOI":"10.1152\/ajprenal.90765.2008","article-title":"Differential regulation of the renal sodium-phosphate cotransporters NaPi-IIa, NaPi-IIc, and PiT-2 in dietary potassium deficiency","volume":"297","author":"Breusegem","year":"2009","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.eprac.2022.09.007_bib16","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/s41581-019-0159-y","article-title":"Mechanisms of phosphate transport","volume":"15","author":"Levi","year":"2019","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.eprac.2022.09.007_bib17","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/nrneph.2010.17","article-title":"Recent advances in renal phosphate handling","volume":"6","author":"Farrow","year":"2010","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.eprac.2022.09.007_bib18","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1056\/NEJM199406093302304","article-title":"Brief report: inhibition of renal phosphate transport by a tumor product in a patient with oncogenic osteomalacia","volume":"330","author":"Cai","year":"1994","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.eprac.2022.09.007_bib19","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1056\/NEJM199406093302310","article-title":"Tumor-induced osteomalacia--unveiling a new hormone","volume":"330","author":"Econs","year":"1994","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.eprac.2022.09.007_bib20","doi-asserted-by":"crossref","first-page":"496514","DOI":"10.1186\/1687-9856-2009-496514","article-title":"Fibroblast growth factor 23 (FGF23) and disorders of phosphate metabolism","volume":"2009","author":"Saito","year":"2009","journal-title":"Int J Pediatr Endocrinol"},{"key":"10.1016\/j.eprac.2022.09.007_bib21","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1210\/jc.2006-2865","article-title":"Determination of the elimination half-life of fibroblast growth factor-23","volume":"92","author":"Khosravi","year":"2007","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.eprac.2022.09.007_bib22","doi-asserted-by":"crossref","first-page":"R23","DOI":"10.1530\/JME-20-0178","article-title":"FGF23 signalling and physiology","volume":"66","author":"Ho","year":"2021","journal-title":"J\u00a0Mol Endocrinol"},{"key":"10.1016\/j.eprac.2022.09.007_bib23","doi-asserted-by":"crossref","first-page":"3891","DOI":"10.1210\/en.2014-1199","article-title":"Genetic rescue of glycosylation-deficient Fgf23 in the Galnt3 knockout mouse","volume":"155","author":"Ichikawa","year":"2014","journal-title":"Endocrinology"},{"key":"10.1016\/j.eprac.2022.09.007_bib24","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1038\/ki.2015.22","article-title":"Differential expression and regulation of Klotho by paricalcitol in the kidney, parathyroid, and aorta of uremic rats","volume":"87","author":"Ritter","year":"2015","journal-title":"Kidney Int"},{"key":"10.1016\/j.eprac.2022.09.007_bib25","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1073\/pnas.0902006107","article-title":"Isolated C-terminal tail of FGF23 alleviates hypophosphatemia by inhibiting FGF23-FGFR-Klotho complex formation","volume":"107","author":"Goetz","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.eprac.2022.09.007_bib26","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41581-019-0189-5","article-title":"FGF23 at the crossroads of phosphate, iron economy and erythropoiesis","volume":"16","author":"Edmonston","year":"2020","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.eprac.2022.09.007_bib27","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1186\/s12882-020-01826-5","article-title":"Interaction between serum FGF-23 and PTH in renal phosphate excretion, a case-control study in hypoparathyroid patients","volume":"21","author":"Saki","year":"2020","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.eprac.2022.09.007_bib28","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1210\/jcem-60-4-711","article-title":"The concurrence of hypoparathyroidism provides new insights to the pathophysiology of X-linked hypophosphatemic rickets","volume":"60","author":"Lyles","year":"1985","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.eprac.2022.09.007_bib29","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1681\/ASN.2012010048","article-title":"Targeted deletion of Klotho in kidney distal tubule disrupts mineral metabolism","volume":"23","author":"Olauson","year":"2012","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.eprac.2022.09.007_bib30","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1038\/ki.2011.26","article-title":"Phosphate and Klotho","volume":"79","author":"Kuro","year":"2011","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.eprac.2022.09.007_bib31","doi-asserted-by":"crossref","first-page":"e1003975","DOI":"10.1371\/journal.pgen.1003975","article-title":"Parathyroid-specific deletion of Klotho unravels a novel calcineurin-dependent FGF23 signaling pathway that regulates PTH secretion","volume":"9","author":"Olauson","year":"2013","journal-title":"PLoS Genet"},{"key":"10.1016\/j.eprac.2022.09.007_bib32","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1359\/jbmr.2002.17.6.1102","article-title":"Tumors associated with oncogenic osteomalacia express genes important in bone and mineral metabolism","volume":"17","author":"De Beur","year":"2002","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.eprac.2022.09.007_bib33","doi-asserted-by":"crossref","first-page":"e2299","DOI":"10.1210\/clinem\/dgaa964","article-title":"Paraneoplastic secretion of multiple phosphatonins from a deep fibrous histiocytoma causing oncogenic osteomalacia","volume":"106","author":"Leow","year":"2021","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.eprac.2022.09.007_bib34","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1677\/joe.1.05989","article-title":"Serum MEPE-ASARM-peptides are elevated in X-linked rickets (HYP): implications for phosphaturia and rickets","volume":"183","author":"Bresler","year":"2004","journal-title":"J\u00a0Endocrinol"},{"key":"10.1016\/j.eprac.2022.09.007_bib35","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.bone.2003.10.005","article-title":"MEPE has the properties of an osteoblastic phosphatonin and minhibin","volume":"34","author":"Rowe","year":"2004","journal-title":"Bone"},{"key":"10.1016\/j.eprac.2022.09.007_bib36","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.bone.2004.09.015","article-title":"Surface plasmon resonance (SPR) confirms that MEPE binds to PHEX via the MEPE-ASARM motif: a model for impaired mineralization in X-linked rickets (HYP)","volume":"36","author":"Rowe","year":"2005","journal-title":"Bone"},{"key":"10.1016\/j.eprac.2022.09.007_bib37","first-page":"722","article-title":"Aberrant Phex function in osteoblasts and osteocytes alone underlies murine X-linked hypophosphatemia","volume":"118","author":"Yuan","year":"2008","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.eprac.2022.09.007_bib38","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s00424-005-1495-2","article-title":"Secreted frizzled-related protein-4 reduces sodium-phosphate co-transporter abundance and activity in proximal tubule cells","volume":"451","author":"Berndt","year":"2006","journal-title":"Pflugers Arch"},{"key":"10.1016\/j.eprac.2022.09.007_bib39","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1172\/JCI18563","article-title":"Secreted frizzled-related protein 4 is a potent tumor-derived phosphaturic agent","volume":"112","author":"Berndt","year":"2003","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.eprac.2022.09.007_bib40","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1210\/en.2010-1351","article-title":"Genetic ablation of sfrp4 in mice does not affect serum phosphate homeostasis","volume":"152","author":"Christov","year":"2011","journal-title":"Endocrinology"},{"key":"10.1016\/j.eprac.2022.09.007_bib41","doi-asserted-by":"crossref","first-page":"p23","DOI":"10.1159\/000093277","article-title":"FGF-23 and sFRP-4 in chronic kidney disease and post-renal transplantation","volume":"104","author":"Pande","year":"2006","journal-title":"Nephron Physiol"},{"key":"10.1016\/j.eprac.2022.09.007_bib42","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1210\/jc.2004-0357","article-title":"Fibroblast growth factor 7: an inhibitor of phosphate transport derived from oncogenic osteomalacia-causing tumors","volume":"90","author":"Carpenter","year":"2005","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.eprac.2022.09.007_bib43","doi-asserted-by":"crossref","first-page":"115300","DOI":"10.1016\/j.bone.2020.115300","article-title":"Hyperphosphatemia with low FGF7 and normal FGF23 and sFRP4 levels in the circulation characterizes pediatric hypophosphatasia","volume":"134","author":"Whyte","year":"2020","journal-title":"Bone"},{"key":"10.1016\/j.eprac.2022.09.007_bib44","doi-asserted-by":"crossref","first-page":"57","DOI":"10.5414\/CN108596","article-title":"Tumor induced osteomalacia: associated with elevated circulating levels of fibroblast growth factor-7 in addition to fibroblast growth factor-23","volume":"85","author":"Bansal","year":"2016","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.eprac.2022.09.007_bib45","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/nrneph.2010.121","article-title":"Hereditary disorders of renal phosphate wasting","volume":"6","author":"Alizadeh Naderi","year":"2010","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.eprac.2022.09.007_bib46","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s00223-020-00692-5","article-title":"Congenital conditions of hypophosphatemia in children","volume":"108","author":"Imel","year":"2021","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.eprac.2022.09.007_bib47","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/s41574-022-00662-x","article-title":"Interdisciplinary management of FGF23-related phosphate wasting syndromes: a consensus statement on the evaluation, diagnosis and care of patients with X-linked hypophosphataemia","volume":"18","author":"Trombetti","year":"2022","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.eprac.2022.09.007_bib48","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/jbmr.1738","article-title":"Hexa-D-arginine treatment increases 7B2\u2217PC2 activity in hyp-mouse osteoblasts and rescues the HYP phenotype","volume":"28","author":"Yuan","year":"2013","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.eprac.2022.09.007_bib49","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s00223-020-00695-2","article-title":"Congenital conditions of hypophosphatemia expressed in adults","volume":"108","author":"Marcucci","year":"2021","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.eprac.2022.09.007_bib50","doi-asserted-by":"crossref","first-page":"9637","DOI":"10.1073\/pnas.0502249102","article-title":"Hypophosphatemia leads to rickets by impairing caspase-mediated apoptosis of hypertrophic chondrocytes","volume":"102","author":"Sabbagh","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.eprac.2022.09.007_bib51","doi-asserted-by":"crossref","first-page":"e1002427","DOI":"10.1371\/journal.pbio.1002427","article-title":"Excessive osteocytic Fgf23 secretion contributes to pyrophosphate accumulation and mineralization defect in hyp mice","volume":"14","author":"Murali","year":"2016","journal-title":"PLoS Biol"},{"key":"10.1016\/j.eprac.2022.09.007_bib52","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1002\/jcp.22244","article-title":"1Alpha,25-(OH)2D3 acts in the early phase of osteoblast differentiation to enhance mineralization via accelerated production of mature matrix vesicles","volume":"225","author":"Woeckel","year":"2010","journal-title":"J\u00a0Cell Physiol"},{"key":"10.1016\/j.eprac.2022.09.007_bib53","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.bone.2017.01.034","article-title":"Heritable and acquired disorders of phosphate metabolism: etiologies involving FGF23 and current therapeutics","volume":"102","author":"Clinkenbeard","year":"2017","journal-title":"Bone"},{"key":"10.1016\/j.eprac.2022.09.007_bib54","doi-asserted-by":"crossref","first-page":"E1146","DOI":"10.1073\/pnas.1110905108","article-title":"Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice","volume":"108","author":"Farrow","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.eprac.2022.09.007_bib55","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s00198-020-05649-w","article-title":"Iron deficiency plays essential roles in the trigger, treatment, and prognosis of autosomal dominant hypophosphatemic rickets","volume":"32","author":"Liu","year":"2021","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.eprac.2022.09.007_bib56","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/jbmr.3878","article-title":"Oral iron replacement normalizes fibroblast growth factor 23 in iron-deficient patients with autosomal dominant hypophosphatemic rickets","volume":"35","author":"Imel","year":"2020","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.eprac.2022.09.007_bib57","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/MNH.0000000000000329","article-title":"Iron-induced hypophosphatemia: an emerging complication","volume":"26","author":"Zoller","year":"2017","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.eprac.2022.09.007_bib58","doi-asserted-by":"crossref","first-page":"e124486","DOI":"10.1172\/jci.insight.124486","article-title":"Randomized trial of intravenous iron-induced hypophosphatemia","volume":"3","author":"Wolf","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.eprac.2022.09.007_bib59","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1001\/jama.2019.22450","article-title":"Effects of iron isomaltoside vs ferric carboxymaltose on hypophosphatemia in iron-deficiency anemia: two randomized clinical trials","volume":"323","author":"Wolf","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.eprac.2022.09.007_bib60","doi-asserted-by":"crossref","first-page":"116111","DOI":"10.1016\/j.bone.2021.116111","article-title":"Autosomal recessive hypophosphatemic rickets type 2 (ARHR2) due to ENPP1-deficiency","volume":"153","author":"Hoppner","year":"2021","journal-title":"Bone"},{"key":"10.1016\/j.eprac.2022.09.007_bib61","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/ng1221","article-title":"Mutations in ENPP1 are associated with \u2018idiopathic\u2019 infantile arterial calcification","volume":"34","author":"Rutsch","year":"2003","journal-title":"Nat Genet"},{"key":"10.1016\/j.eprac.2022.09.007_bib62","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1056\/NEJM199112123252403","article-title":"Activating mutations of the stimulatory G protein in the McCune-Albright syndrome","volume":"325","author":"Weinstein","year":"1991","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.eprac.2022.09.007_bib63","doi-asserted-by":"crossref","first-page":"5152","DOI":"10.1073\/pnas.89.11.5152","article-title":"Identification of a mutation in the gene encoding the alpha subunit of the stimulatory G protein of adenylyl cyclase in McCune-Albright syndrome","volume":"89","author":"Schwindinger","year":"1992","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.eprac.2022.09.007_bib64","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1056\/NEJMc1808583","article-title":"Mosaic effects of growth hormone on fibrous dysplasia of bone","volume":"379","author":"Roszko","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.eprac.2022.09.007_bib65","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1172\/JCI18399","article-title":"FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting","volume":"112","author":"Riminucci","year":"2003","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.eprac.2022.09.007_bib66","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1053\/j.semdp.2019.07.002","article-title":"Phosphaturic mesenchymal tumors: a review and update","volume":"36","author":"Folpe","year":"2019","journal-title":"Semin Diagn Pathol"},{"key":"10.1016\/j.eprac.2022.09.007_bib67","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1007\/s00223-020-00691-6","article-title":"Tumor-induced osteomalacia","volume":"108","author":"Florenzano","year":"2021","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.eprac.2022.09.007_bib68","doi-asserted-by":"crossref","first-page":"116064","DOI":"10.1016\/j.bone.2021.116064","article-title":"Challenges in the management of tumor-induced osteomalacia (TIO)","volume":"152","author":"Brandi","year":"2021","journal-title":"Bone"},{"key":"10.1016\/j.eprac.2022.09.007_bib69","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1210\/jc.2005-2105","article-title":"Sensitivity of fibroblast growth factor 23 measurements in tumor-induced osteomalacia","volume":"91","author":"Imel","year":"2006","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.eprac.2022.09.007_bib70","doi-asserted-by":"crossref","first-page":"116077","DOI":"10.1016\/j.bone.2021.116077","article-title":"Tumor induced osteomalacia: a single center experience on 17 patients","volume":"152","author":"Crotti","year":"2021","journal-title":"Bone"},{"key":"10.1016\/j.eprac.2022.09.007_bib71","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1002\/jbmr.4325","article-title":"Impaired bone microarchitecture and strength in patients with tumor-induced osteomalacia","volume":"36","author":"Zanchetta","year":"2021","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.eprac.2022.09.007_bib72","doi-asserted-by":"crossref","first-page":"883981","DOI":"10.3389\/fendo.2022.883981","article-title":"Bone volumetric density, microarchitecture, and estimated bone strength in tumor-induced rickets\/osteomalacia versus X-linked hypophosphatemia in Chinese adolescents","volume":"13","author":"Jiajue","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.eprac.2022.09.007_bib73","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/jbmr.4476","article-title":"Bone impairment in a large cohort of Chinese patients with tumor-induced osteomalacia assessed by HR-pQCT and TBS","volume":"37","author":"Ni","year":"2022","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.eprac.2022.09.007_bib74","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s12020-022-03039-2","article-title":"Persistence and recurrence in tumor-induced osteomalacia: a systematic review of the literature and results from a national survey\/case series","volume":"76","author":"Cianferotti","year":"2022","journal-title":"Endocrine"},{"issue":"8","key":"10.1016\/j.eprac.2022.09.007_bib75","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1002\/jbmr.4620","article-title":"Clinical challenges in diagnosis, tumor localization and treatment of tumor-induced osteomalacia: outcome of a retrospective surveillance","volume":"37","author":"Hidaka","year":"2022","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.eprac.2022.09.007_bib76","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1111\/j.1365-2796.2010.02262.x","article-title":"Clinical utility of systemic venous sampling of FGF23 for identifying tumours responsible for tumour-induced osteomalacia","volume":"268","author":"Ito","year":"2010","journal-title":"J\u00a0Intern Med"},{"key":"10.1016\/j.eprac.2022.09.007_bib77","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/ncpneph0124","article-title":"Hypophosphatemia: an evidence-based approach to its clinical consequences and management","volume":"2","author":"Amanzadeh","year":"2006","journal-title":"Nat Clin Pract Nephrol"},{"key":"10.1016\/j.eprac.2022.09.007_bib78","doi-asserted-by":"crossref","DOI":"10.1007\/s00223-022-00987-9","article-title":"The measurement and interpretation of fibroblast growth factor 23 (FGF23) concentrations","author":"Heijboer","year":"2022","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.eprac.2022.09.007_bib79","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s00774-021-01258-7","article-title":"Performance evaluation of the new chemiluminescent intact FGF23 assay relative to the existing assay system","volume":"40","author":"Kato","year":"2022","journal-title":"J\u00a0Bone Miner Metab"},{"key":"10.1016\/j.eprac.2022.09.007_bib80","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/j.bone.2008.02.014","article-title":"Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23) in hypophosphatemic patients: proposal of diagnostic criteria using FGF23 measurement","volume":"42","author":"Endo","year":"2008","journal-title":"Bone"},{"key":"10.1016\/j.eprac.2022.09.007_bib81","doi-asserted-by":"crossref","first-page":"e267","DOI":"10.1515\/cclm-2020-0460","article-title":"FGF23 measurement in burosumab-treated patients: an emerging treatment may induce a new analytical interference","volume":"58","author":"Piketty","year":"2020","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.eprac.2022.09.007_bib82","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1056\/NEJMoa1714641","article-title":"Burosumab therapy in children with X-linked hypophosphatemia","volume":"378","author":"Carpenter","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.eprac.2022.09.007_bib83","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1016\/S0140-6736(19)30654-3","article-title":"Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial","volume":"393","author":"Imel","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.eprac.2022.09.007_bib84","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S2213-8587(18)30338-3","article-title":"Efficacy and safety of burosumab in children aged 1-4 years with X-linked hypophosphataemia: a multicentre, open-label, phase 2 trial","volume":"7","author":"Whyte","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.eprac.2022.09.007_bib85","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1007\/s00223-020-00797-x","article-title":"Patient-reported outcomes from a randomized, active-controlled, open-label, phase 3 trial of burosumab versus conventional therapy in children with X-linked hypophosphatemia","volume":"108","author":"Padidela","year":"2021","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.eprac.2022.09.007_bib86","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.1210\/clinem\/dgac296","article-title":"Impact of burosumab compared with conventional therapy in younger versus older children with X-linked hypophosphatemia","volume":"107","author":"Ward","year":"2022","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.eprac.2022.09.007_bib87","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1002\/jbmr.3475","article-title":"A\u00a0randomized, double-blind, placebo-controlled, phase 3 trial evaluating the efficacy of burosumab, an anti-FGF23 antibody, in adults with X-linked hypophosphatemia: week 24 primary analysis","volume":"33","author":"Insogna","year":"2018","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.eprac.2022.09.007_bib88","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s00223-019-00568-3","article-title":"Continued beneficial effects of burosumab in adults with X-linked hypophosphatemia: results from a 24-week treatment continuation period after a 24-week double-blind placebo-controlled period","volume":"105","author":"Portale","year":"2019","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.eprac.2022.09.007_bib89","doi-asserted-by":"crossref","first-page":"e001714","DOI":"10.1136\/rmdopen-2021-001714","article-title":"Burosumab treatment in adults with X-linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extension","volume":"7","author":"Briot","year":"2021","journal-title":"RMD Open"},{"key":"10.1016\/j.eprac.2022.09.007_bib90","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1002\/jbmr.3843","article-title":"Burosumab improved histomorphometric measures of osteomalacia in adults with X-linked hypophosphatemia: a phase 3, single-arm, international trial","volume":"34","author":"Insogna","year":"2019","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.eprac.2022.09.007_bib91","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1002\/jbmr.4233","article-title":"Burosumab for the treatment of tumor-induced osteomalacia","volume":"36","author":"Jan de Beur","year":"2021","journal-title":"J\u00a0Bone Miner Res"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X22006255?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X22006255?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:14:50Z","timestamp":1761516890000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X22006255"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":91,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S1530891X22006255"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2022.09.007","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phosphatonins: From Discovery to Therapeutics","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2022.09.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Inc. on behalf of the AACE.","name":"copyright","label":"Copyright"}]}}